Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184/c-Myc axis

JINHUA WANG1,2, XIAOHUI YANG2, RONG LI2, LIANG WANG3, YINMIN GU2, YUHUI ZHAO3, KUO HSIAANG HUANG2, TIANYOU CHENG4, YI YUAN5 and SHAN GAO2,4,5

1School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230026; 2CAS Key Laboratory of Bio-medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, Jiangsu 215163; 3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101; 4Shanxi Academy of Advanced Research and Innovation, Taiyuan, Shanxi 030032; 5Medical College, Guizhou University, Guiyang, Guizhou 550025, P.R. China

Received February 26, 2018; Accepted August 13, 2018

DOI: 10.3892/or.2018.6661

Correspondence to: Professor Shan Gao, CAS Key Laboratory of Bio-medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, 88 Keling Road, High-tech District, Suzhou, Jiangsu 215163, P.R. China
E-mail: gaos@sibet.ac.cn

Key words: prostate cancer, long non-coding RNA, MYU, miR-184, c-Myc

Abstract. Long non-coding RNAs (lncRNAs) play critical roles in tumorigenesis and cancer progression. The c-Myc upregulated lncRNA MYU (VPS9D1 antisense RNA1, annotated as VPS9D1-AS1) has been reported in several common types of human cancers, which has revealed that lncRNA MYU could function as either an oncogene or a tumor-suppressor gene in different cancer types. However, the function of lncRNA MYU in prostate cancer remains unknown. In the present study, we demonstrated that lncRNA MYU is significantly upregulated in prostate cancer tissues. MYU knockdown impaired prostate cancer cell growth and migration as shown from cell viability, colony formation, Transwell and wound healing assays. In contrast, MYU overexpression displayed opposite effects. No correlation was noted between MYU and its cognate VPS9D1 expression level. Moreover, lncRNA MYU did not regulate the expression of VPS9D1 either at the mRNA or protein level as detected using qRT-PCR and western blotting assays. Furthermore, lncRNA MYU was able to be transported into the extracellular milieu by means of exosomes, and then promoted adjacent cell proliferation and migration. Mechanistically, lncRNA MYU upregulated c-Myc by competitively binding miR-184 and then induced the proliferation of prostate cancer. Thus, this study demonstrated that lncRNA MYU functions as an oncogene in prostate cancer at least in part through the miR-184/c-Myc axis, and may serve as a potential diagnostic biomarker and therapeutic target.

Introduction

Prostate cancer (PCa) is the most common non-cutaneous malignancy in men (1). PCa tumorigenesis is involved in multiple genomic alterations (2). For example, the oncogene c-Myc is upregulated in PCa, which is associated with tumor progression (3,4). A previous study revealed that an HP1γ/miR-451a/c-Myc feedback loop exists in PCa cells and this loop is essential for PCa development (5). However, the underlying molecular mechanisms of c-Myc in PCa remain incompletely understood.

Accumulating evidence indicates that non-coding RNAs (ncRNAs), such as microRNAs (miRNAs, <200 nt) and long ncRNAs (lncRNAs, >200 nt) (6), are involved in numerous processes of tumorigenesis (7,8). Accumulating data suggest that lncRNAs, such as PCA3 (9), PCAT-1 (4), SchLAP1 (10), PCGEM1 and PRNCR1 (11) play important roles in PCa tumorigenesis. lncRNAs can regulate coding gene mRNAs via competitively binding to co-target miRNAs, termed as competing endogenous RNA (ceRNA) network, thus functioning in cancer (12,13). The molecular mechanism of most lncRNAs in PCa remains unknown due to their enormousness.

A c-Myc-upregulated lncRNA MYU (ENSG00000261373) has been reported to exert an oncogenic effect in colorectal cancer (CRC) (14,15), but functions as a tumor-suppressor gene in gastric cancer (GC) (16). A recent study suggests that MYU as a target for Wnt/c-Myc signaling can promote cell cycle progression by stabilizing CDK6 expression via associating with hnRNP-K (14). However, the functional roles and underlying molecular mechanisms of MYU in PCa have not been explored. Thus, we were motivated to study the roles of MYU in PCa.

In the present study, we revealed the clinical significance and function of MYU in PCa, and demonstrated that MYU promotes the progression of PCa as a ceRNA to modulate miR-184 binding, consequently regulating c-Myc expression. Our results shed new light on the prospect for MYU as a potential novel diagnostic biomarker as well as a therapeutic target.
Materials and methods

Cell culture. Human PCa cell lines DU145, PC3, 22Rv1 and LNCaP were obtained from the Shanghai Institute of Biochemistry and Cell Biology (CAS). Lenti-X™ 293T cells were obtained from Clontech Laboratories, Inc. (Mountainview, CA, USA). Cell lines were cultured routinely in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) or DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS, Gibco; Thermo Fisher Scientific, Inc.), penicillin and streptomycin (x1.00). All cell lines were maintained in 5% CO₂ at 37°C. PCR detection method was used to check mycoplasma contamination. All cell lines were verified using short tandem repeat assays by Genetic Testing Biotechnology, Suzhou, China.

5′/3′ Rapid amplification of cDNA ends (5′/3′ RACE). The complementary DNA (cDNA) was synthesized using RNA (1.0 µg) extracted from PC3 cells. The 5′/3′ RACE was carried out using the SMARTer™ RACE cDNA Amplification kit (Clontech Laboratories, Inc.) according to the manufacturer’s instructions. The gene-specific primers used for the PCR of the RACE analysis are given in Table 1.

Plasmid construction. The full-length of MYU (Fig. 1) and VPS9D1, which is fused with a FLAG epitope tag with the C terminus, Fig. 2) were subcloned into pLXV-IRE-Neo vector. The short hairpin RNAs (shRNAs) that target different sites of MYU, VPS9D1 and c-Myc CDS region were inserted into the pSHI-H1 vector. The shRNA primers are listed in Table II. MYU full-length and 3′ untranslated regions (UTR) of c-Myc containing the miR-184 binding sites were synthesized in the dual luciferase reporter vector pmirGLO (Promega Corporation, Madison, WI, USA).

RNA extraction, quantitative real-time PCR (qRT-PCR) and Western blotting. Total RNA was isolated from PCa cells using RNAiso Plus reagent (Takara, Shiga, Japan) and RNA (1 µg) was reverse transcribed using the PrimerScript RT-PCR kit (Takara) according to the manufacturer’s instructions. The expression levels of MYU were determined by qRT-PCR using the SYBR® Green dye (Takara) detection method. We used the comparative Ct method to quantify transcripts. The relative gene expression was defined using the equation: ΔCt= Ct target - Ct reference, and the fold-change for target genes normalized by GAPDH was determined by the formula 2-ΔΔCt.

Equivalent quantities of proteins were loaded to each lane. Proteins was examined using BCA protein kit (Beyotime). The concentration of total proteins was determined by sodium dodecyl sulfate (SDS) loading buffer (Beyotime). The concentration of total proteins was examined using BCA protein kit (Beyotime). Equivalent quantities of proteins were loaded to each lane. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate proteins and then the proteins were transferred from the gel onto NC or PVDF membranes. Membranes were incubated with primary antibodies against GAPDH (AG019, 1:5,000), H3 (AH433, 1:5,000) and β-actin (AA128, 1:5,000) all from Beyotime, Flag (F3165, 1:1,000) from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany), ZO-1 (8193S, 1:1,000), caludin-1 (13995S, 1:1,000), E-cadherin (3195S, 1:1,000), and c-Myc (13987S, 1:1,000) from Cell Signaling Technology, Inc. (Danvers, MA, USA), N-cadherin (ab76011, 1:1,000), vimentin (ab92547, 1:1,000) from Abcam (Cambridge, MA, USA). After incubation with suitable HRP-conjugated secondary antibodies, immunoreactive proteins were finally visualized using ECL chemiluminescence system (CLiNX, Shanghai, China). All qRT-PCR primers are listed in Table III.

Subcellular fractionation. LNCaP cells were captured with 1 ml PBS and 200 µl were extracted as the positive control, the remainder were snap-frozen with liquid nitrogen and then quickly dissolved in a water bath, repeating this operation twice. Then, 200 µl buffer A1 (10 mM HEPES, pH 7.9, 1.5 mM MgCl₂, 10 mM KCl, 0.1% NP-40 and 1% protease inhibitor) was added to the cells, and ground 15-20 times with a grinding pestle. After incubation on ice for 5 min, the lysate was centrifuged at 2,000 rpm for 5 min at 4°C. The supernatant was used to separate the cytoplasmic fraction. The remaining pellet was resuspended in 200 µl of buffer A2 (10 mM HEPES, pH 7.9, 1.5 mM MgCl₂, 10 mM KCl, and 1% protease inhibitor) and ground 5-10 times with a grinding pestle. Then, the lysate was resuspended in another 300 µl of buffer A2. After incubating on ice for 5 min, the lysate was centrifuged at 2000 rpm for 5 min at 4°C. The remaining pellet was resuspended in 500 µl of buffer S1 (0.25 mM sucrose, 10 mM MgCl₂, and 1% protease inhibitor), and then added 500 µl of buffer S2 (0.35 mM sucrose, 0.5 mM MgCl₂, and 1% protease inhibitor) and incubated on ice for 30 min. The supernatant containing the nuclear fraction was collected by centrifugation at 12,000 rpm for 15 min at 4°C. The qRT-PCR and western blot analysis were used to assess the total RNA and protein isolated from the subcellular fractions. GAPDH served as the cytoplasmic control, and U1 as nuclear control. GAPDH, U1 and MYU expression levels were measured by qRT-PCR.

Cell transfection. The packaging plasmids, recombined plasmids and LNAs for overexpression and knockdown were transfected into Lenti-X™ 293T cells. Two LNAs (LNA-1 and LNA-2) and LNA-Ctrl (300610, Negative control A

<table>
<thead>
<tr>
<th>Primers</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>5′ TCTGTGGAAAGTGCCGTTTT 3′</td>
</tr>
<tr>
<td>P2</td>
<td>5′ GGCGTCCAAGATGGAGGAGTG 3′</td>
</tr>
<tr>
<td>P3</td>
<td>5′ CTGTTGCAATCCATGAGGACGCTG 3′</td>
</tr>
<tr>
<td>P4</td>
<td>5′ CATGCCCAGCTACGGGAAAGG 3′</td>
</tr>
<tr>
<td>P5</td>
<td>5′ TCTGTCCTCTGGGACCTTTTCGCTC 3′</td>
</tr>
<tr>
<td>P6</td>
<td>5′ AGGATGGGAGCAGTAAACGGG 3′</td>
</tr>
<tr>
<td>5′-F</td>
<td>5′ AGGGCGTCTGACCCGCGC 3′</td>
</tr>
<tr>
<td>3′-R</td>
<td>5′ ATCTCCCGAAGTTCATAGAAGAGGTTG 3′</td>
</tr>
<tr>
<td>GSP1</td>
<td>5′ GATTACGCAAGCTTTTTCGCTGCCTCGCCCTATCGCC 3′</td>
</tr>
<tr>
<td>GSP2</td>
<td>5′ GATTACGCAAGCTTGCGCAGATGGGGCGAGGCAAA 3′</td>
</tr>
</tbody>
</table>

Table I. Primers for the 5′/3′ RACE.
Antisense LNA GapmeR) were purchased from Exiqon A/S (Vedbaek, Denmark). The hsa-miR-184 (miR-184) mimics and the negative control miR-NC were purchased from RiboBio (Guangzhou, China). Cells were harvested 48 h after transfection. These corresponding plasmids or miRNA mimics were transfected with PEI or Lipofectamine 3000 (Invitrogen; Thermo Fisher Scientific, Inc.). The final concentrations of miRNAs/LNAs employed in this study were as follows: miR-184 mimic/negative control mimic 50 nM/ml and LNA-1/LNA-2/LNA-Ctrl 50 nM/ml.

Cell viability, colony formation and migration assay. Cells were seeded into 96-well plates at a density of 1.0x10^4 cells/well. Cell viability was assessed using CellTiter-Glo (CTG) reagent (Promega Corporation) every 48 h following the manufacturer's instructions. In addition, 1.0x10^4 cells were seeded per well of 6-well plates. After 2 weeks, the number of clones was counted with staining using ImageJ (https://imagej.nih.gov/ij/). Wound healing and Transwell chamber assays were performed to determine cell migration ability. For wound healing assay, cells were seeded into two well silicones (ibidi, GmbH, Munich, Germany) in 24-well plates. When the cell density reached 90-100% confluence, the inserts were removed and washed with PBS, and then cultured with serum-free medium. Images were collected at 0 and 24 h under an inverted microscope (Zeiss,

Figure 1. The nucleotide sequence of full-length MYU. MYU is a 1,461 bp transcript with four exons.
WANG et al: LONG NON-CODING RNA MYU PROMOTES PROSTATE CANCER PROLIFERATION

3.5x10^4 cells/well in 200 µl, was added to an 8.0-µm pore-size insert of a 24-well plate. The lower well contained 500 µl exosomes and 10% FBS. The Transwell plate was then incubated for 24 h at 37˚C with 5% CO2. Hereafter, the cells on the top surface of the insert were wiped off and the cells on the lower surface of the insert were fixed with 95% ethanol for 10-15 min, and then dyed with 0.5% crystal violet. Images were collected under an inverted microscope. Finally, the cells were decolorized with 95% ethanol and the same amount of eluent was used to measure the absorbance at 580 nm wavelength. These experiments were conducted in triplicate.

Exosome isolation and treatment. PC3 cells were grown to a 70-80% confluent monolayer, washed three times with PBS, and grown in serum-free culture medium for 3 days. Exosomes were collected by gradient centrifugation, cleaned by PBS, and stored at -80˚C.

Exosomes were isolated from the MYU-overexpressing or control PC3 supernatant. An appropriate amount of serum-free 1640 medium was added and filtered with a 0.22-µm filter. For cell viability assay, PC3 cells were plated in a 96-well plate on the first day, and then treated with exosomes from MYU-overexpressing or control PC3 cells, which were assessed by CTG assays after incubation for 5 days. For Transwell assays, the PC3 cell suspension, 3.5x10^4 cells/well in 200 µl, was added to an 8.0-µm pore-size insert of a 24-well plate. The lower well contained 500 µl exosomes and 10% FBS. The Transwell plate was then incubated for 24 h at 37˚C with 5% CO2.

Exosomes were collected by gradient centrifugation, cleaned by PBS, and stored at -80˚C.

Exosomes were isolated from the MYU-overexpressing or control PC3 supernatant. An appropriate amount of serum-free 1640 medium was added and filtered with a 0.22-µm filter. For cell viability assay, PC3 cells were plated in a 96-well plate on the first day, and then treated with exosomes from MYU-overexpressing or control PC3 cells, which were assessed by CTG assays after incubation for 5 days. For Transwell assays, the PC3 cell suspension, 3.5x10^4 cells/well in 200 µl, was added to an 8.0-µm pore-size insert of a 24-well plate. The lower well contained 500 µl exosomes and 10% FBS. The Transwell plate was then incubated for 24 h at 37˚C with 5% CO2.

Dual luciferase reporter assay. Lenti-X™ 293T cells grown in a 24-well plate were co-transfected with 200 ng of dual luciferase reporter vector comprising MYU and its mutant or 3'UTR of c-Myc, 50 nM miRNA mimics using Lipofectamine 3000. Cells were harvested 48 h after transfection and analyzed using the dual luciferase reporter assay kit (Promega Corporation) with a microplate reader (BioTek Instruments, Inc., Winooski, VT, USA) according to the manufacturer's protocol.

Table II. Primer sequences of MYU, VPS9D1 and c-Myc shRNAs.

<table>
<thead>
<tr>
<th>shRNA</th>
<th>Primers</th>
<th>Primer sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>MYU shRNA-1</td>
<td>Forward</td>
<td>5' GATCCGACATGGACTGTGCTACTAGTGAAGAAGAGCTGCTTCTTTTTG 3'</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>5' AATTCACCATGGTACGGGTGTGTTGTTGTTG 3'</td>
</tr>
<tr>
<td>MYU shRNA-2</td>
<td>Forward</td>
<td>5' GATCCGACATGGACTGTGCTACTAGTGAAGAAGAGCTGCTTCTTTTTG 3'</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>5' AATTCACCATGGTACGGGTGTGTTGTTGTTG 3'</td>
</tr>
<tr>
<td>VPS9D1 shRNA-1</td>
<td>Forward</td>
<td>5' GATCCGACATGGACTGTGCTACTAGTGAAGAAGAGCTGCTTCTTTTTG 3'</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>5' AATTCACCATGGTACGGGTGTGTTGTTGTTG 3'</td>
</tr>
<tr>
<td>c-Myc shRNA</td>
<td>Forward</td>
<td>5' GATCCGACATGGACTGTGCTACTAGTGAAGAAGAGCTGCTTCTTTTTG 3'</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>5' AATTCACCATGGTACGGGTGTGTTGTTGTTG 3'</td>
</tr>
</tbody>
</table>

Table III. qPCR sequences of MYU, VPS9D1, c-Myc and U1.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primers</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>MYU</td>
<td>Forward</td>
<td>5' AGTGGCCGTTTACACAGGACA 3'</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>5' CATGCAAAGCTAGGGGAGG 3'</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Forward</td>
<td>5' GAGGACAGATCCCTCCCAAAT 3'</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>5' GCTGTTGTCATACTCTTCTTCTG 3'</td>
</tr>
<tr>
<td>VPS9D1</td>
<td>Forward</td>
<td>5' AGATCCCAAATGCGTAGAC 3'</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>5' CTGGAAGCGTGTGTTTAG 3'</td>
</tr>
<tr>
<td>c-Myc</td>
<td>Forward</td>
<td>5' TAGGAAAGCGACCCGCT 3'</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>5' AGGAATACGGCTGCACCGAG 3'</td>
</tr>
<tr>
<td>U1</td>
<td>Forward</td>
<td>5' GGAGATAGCATGCAGAGGAGG 3'</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>5' CCACAAATATACGTGGGTAGGTTCCC 3'</td>
</tr>
</tbody>
</table>

Jena, Germany). Wound healing images were analyzed using ImageJ. For the Transwell chamber assay, the cell suspension, 3.5x10^4 cells/well in 200 µl, was added to a 0.8-µm pore-size insert of a 24-well plate (Corning Costar, Corning, NY, USA). The lower well was filled with 500 µl medium with 10% FBS. The Transwell plate was then incubated for 24 h at 37˚C with 5% CO2. Hereafter, the cells on the top surface of the insert were wiped off and the cells on the lower surface of the insert were fixed with 95% ethanol for 10-15 min, and then dyed with 0.5% crystal violet. Images were collected under an inverted microscope. Finally, the cells were decolorized with 95% ethanol and the same amount of eluent was used to
lncRNA, miRNA, and mRNA expression data. The expression level of lncRNA MYU in prostate adenocarcinoma (PRAD) based on the clinical information was obtained from The Cancer Genome Atlas (TCGA) (17) and the matched expression profiles of lncRNAs from Mitranscriptome. TCGA PRAD patient miRNA expression (Level 3 data, illuminahiseq mirnaseq) and mRNA expression (level 3 data, RNA-seq Version 2) was downloaded from the Broad GDAC Firehose (19).

ChIP-Seq data. Sequencing data from GSE96019, GSE96399 and GSE96418 were downloaded from GEO. Reads from the PC3 H3K4me3, H3K27ac and H3K36me3 ChIP-Seq samples were mapped to human genome version hg19 using HISAT2. Peak calling was performed using MACS (20) according to the published protocols (21). Data were visualized using the UCSC Genome Browser (22).

Statistical analysis. The data were collected and expressed as means ± SEM. Statistical differences (P-values) between two groups were obtained by using a two-tailed Student's t-test. Statistical differences (P-values) in multiple groups were obtained by using a two-way ANOVA analysis. All experiments were carried out in triplicate. A two-tailed P<0.05 was considered to indicate statistical significance. All statistical analyses were undertaken using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA).

Results

MYU is significantly upregulated in PCa. In order to search for the differentially expressed lncRNAs associated with PCa, we analyzed clinical patient data in TCGA and matched expression profiles of lncRNAs from Mitranscriptome. We
noted that IncRNA MYU was significantly upregulated in multiple cancers compared with adjacent normal tissues, and focused on PCa (P<0.0001, Fig. 3A). To investigate the potential cause of higher MYU expression in PCa, we examined the methylation levels of the MYU promoter region, which is a major cause of gene deregulation in tumorigenesis (23). Apparently, the methylation levels of histone H3 of the MYU promoter region in PCa tissues was significantly lower than those of adjacent normal tissues (P=0.0163, Fig. 3B). Moreover, receiver operating characteristic (ROC) curve was used to evaluate the sensitivity and specificity of MYU expression in predicting PCa tissues from normal tissues. MYU displayed considerable predictive significance, with an area under the curve (AUC) of 0.906 (Fig. 3C). In summary, MYU is downregulated in PCa and may be a potentially diagnostic indicator.

The molecular characterization of Myu. To explore the function of MYU more precisely, we performed 5'/3'-RACE to obtain the accurate transcript of MYU, which is a 1,461 bp transcript with four exons (Fig. 3D and Fig. 1). Published PCa chromatin immunoprecipitation and sequencing (ChIP-seq) data confirmed that the transcriptional start site (TSS) of MYU was marked by H3-lysine-27-acetylation (H3K27ac) (24), H3-lysine-4-trimethylation (H3K4me3) (25) and that its gene body harbored H3-lysine-36-trimethylation (H3K36me3) (26), an epigenetic signature consistent with lncRNAs. In addition, the uCSC Genome Browser revealed that MYU sequences across the different species were extremely unconserved (Fig. 3E). The PhyloCSF analysis showed that MYU has no potential protein-coding ability (Fig. 3F). Moreover, subcellular localization of MYU showed about 58% MYU in the nucleus in LNCaP cells (Fig. 3G). Taken together, these data revealed that MYU is an active transcribed IncRNA, which exists both in the nucleus and cytoplasm.

VPS9D1 is not regulated by MYU. We found that MYU has a corresponding sense-cognate coding gene VPS9D1 from the UCSC Genome Browser. Many studies have shown that antisense transcripts regulate the expression of sense genes, particular for ncRNAs as antisense transcripts (27,28). We investigated the potential relationship between MYU and VPS9D1. There was no difference in expression levels of VPS9D1 between PCa tissues and adjacent normal tissues (Fig. 4A). The ROC analysis showed that the AUC of VPS9D1 was 0.621 (Fig. 2B). Moreover, there was no statis-

Figure 4. MYU does not regulate VPS9D1. (A) The expression of VPS9D1 in PCa samples in TCGA (P=0.0773, n=52). (B) The ROC curve analysis of VPS9D1. (C) The correlation analysis between MYU and VPS9D1 in PCa tissues (r=0.0525, P=0.2418). (D) qRT-PCR results of the knockdown of MYU or VPS9D1 in DU145 cells. (E) qRT-PCR results of the overexpression of MYU or VPS9D1 in PCa cells. (F) Western blotting was used to detect the expression of VPS9D1 in DU145 cells. (G) Upper panel: MYU knockdown in VPS9D1 ectopically overexpressed cells was tested by qRT-PCR. Lower panel: western blot assays were used to tested the change in VPS9D1 protein expression after knockdown of MYU in VPS9D1 ectopically overexpressed cells. The data graphs depict numbers from three independent experiments (means ± SEM; *P<0.05, "P<0.01, ""P<0.001). NS, not significant.
A significantly correlation in RNA level between MYU and VPS9D1 (r=0.0525, P=0.2418) (Fig. 4C). Furthermore, we examined the potential regulation between MYU and VPS9D1 using qRT-PCR and western blotting assays. The qRT-PCR results revealed that knockdown of either gene did not affect the mRNA level of another gene (Fig. 4D), and the result of overexpression was the same (Fig. 4E). In order to determine whether MYU expression affected the protein level of VPS9D1, we overexpressed VPS9D1 in Du145 cells (Fig. 4F). Then we knocked down MYU in the VPS9D1-overexpressed cells, and observed the same protein levels of VPS9D1 in either MYU-knockdown or control cells (Fig. 4G). These results suggest that MYU did not regulate VPS9D1 at either the mRNA or protein level. Thus, we focused on studying lncRNA MYU.

**MYU promotes PCa cell proliferation and migration in vitro.** To evaluate the biological effects of MYU on PCa, we firstly performed qRT-PCR to examine MYU expression level in four PCa cell lines (Fig. 5A). To clarify the function of MYU, we established cell lines with stably overexpressed MYU and MYU-specific shRNAs (Fig. 5B). CTG assays indicated that PCa cell proliferation was repressed by MYU shRNAs compared to that of cells stably expressing the scrambled shRNA, whereas enhancement of cell viability occurred after overexpression of MYU (Fig. 5C). Colony formation assay, MYU-upregulated PC3 cells exhibited increased colony growth, while knockdown of MYU in DU145 cells reduced colony growth compared to the control cells (Fig. 5D). Additionally, wound healing (Fig. 5E), Transwell chamber (Fig. 5F) and western blotting (Fig. 5G) assays indicated that
knockdown of MYU reduced the DU145 cell migration rate and the protein level of N-cadherin and vimentin, but increased ZO-1, claudin-1 and E-cadherin. In contrast, overexpression of MYU in the PC3 cells resulted in a higher migration rate, accompanied by downregulated ZO-1, claudin-1 and E-cadherin and upregulated N-cadherin and vimentin. To further confirm these results, we also used locked nucleic acids (LNAs) to knock down the expression of MYU. Similar results for cell viability, clonogenicity and motility were obtained in the DU145 cells (Fig. 6A-F). These results suggest that MYU may act as a non-coding oncogene in PCa cells.

MYU upregulates c-Myc expression by competitively binding miR-184. We aimed to ascertain the potential underlying mechanism of MYU, which may mediate PCA progression. IncRNAs are known to work as sponges to recruit miRNAs, resulting in the activation of miRNA target genes (13,29). We analyzed the correlation of the expression level between MYU and mature miRNAs and found that MYU showed a significantly negative correlation with 15 miRNAs (r < -0.3, P<0.0001, Table V). We then tested if three miRNAs including miR-187-3p, miR-143-3p and miR-184 (r < -0.35, P<0.0001) can bind to MYU. The dual luciferase reporter assays revealed that only miR-184 downregulated the luciferase activity of IncRNA MYU. Then, we searched the reported target coding genes of miR-184 in PubMed. Noteworthy, miR-184 has been reported

Table IV. Sequences of miR-184 mimics and negative control.

<table>
<thead>
<tr>
<th>Mimics</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-184 mimics</td>
<td>5’ UGGACGGGAGAACUGAUAAGGGU 3’</td>
</tr>
<tr>
<td>Negative control</td>
<td>5’ UUCUCGAAGCGUCUCAGUTT 3’</td>
</tr>
</tbody>
</table>

Table V. Fifteen miRNAs show significantly negative correlation with MYU in TCGA PCA tissues (Spearman r < -0.3, P<0.0001).

<table>
<thead>
<tr>
<th>miRNA</th>
<th>Spearman r</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa.miR.187.3p</td>
<td>-0.420633196</td>
<td>1.14E-10</td>
</tr>
<tr>
<td>hsa.miR.221.3p</td>
<td>-0.40755072</td>
<td>4.74E-10</td>
</tr>
<tr>
<td>hsa.miR.143.3p</td>
<td>-0.395310718</td>
<td>1.71E-09</td>
</tr>
<tr>
<td>hsa.miR.873.5p</td>
<td>-0.369065673</td>
<td>2.25E-08</td>
</tr>
<tr>
<td>hsa.miR.187.5p</td>
<td>-0.365681346</td>
<td>3.09E-08</td>
</tr>
<tr>
<td>hsa.miR.184</td>
<td>-0.3619539</td>
<td>4.36E-08</td>
</tr>
<tr>
<td>hsa.miR.378c</td>
<td>-0.359757081</td>
<td>5.33E-08</td>
</tr>
<tr>
<td>hsa.miR.222.3p</td>
<td>-0.350223717</td>
<td>1.25E-07</td>
</tr>
<tr>
<td>hsa.miR.222.5p</td>
<td>-0.349057455</td>
<td>1.39E-07</td>
</tr>
<tr>
<td>hsa.miR.23c</td>
<td>-0.343942199</td>
<td>2.16E-07</td>
</tr>
<tr>
<td>hsa.miR.27b.3p</td>
<td>-0.334526294</td>
<td>4.81E-07</td>
</tr>
<tr>
<td>hsa.miR.133b</td>
<td>-0.332952086</td>
<td>5.48E-07</td>
</tr>
<tr>
<td>hsa.miR.767.5p</td>
<td>-0.327593572</td>
<td>8.51E-07</td>
</tr>
<tr>
<td>hsa.miR.452.5p</td>
<td>-0.31499159</td>
<td>2.32E-06</td>
</tr>
<tr>
<td>hsa.miR.152.3p</td>
<td>-0.306935385</td>
<td>4.30E-06</td>
</tr>
</tbody>
</table>
as a tumor-suppressor gene in multiple cancers (30,31), and downregulated c-Myc expression (32,33). It has been reported that MYU is a direct target of c-Myc (14). We hypothesized that MYU may promote the proliferation of PCa as a ceRNA to sponge miR-184, thus upregulating c-Myc.

TCGA data revealed that miR-184 was significantly downregulated in PCa tissues (Fig. 7A) and negatively correlated with MYU (r=−0.1966, P=0.0037) (Fig. 7B). RNAhybrid (34) was used to predict the binding sites of miR-184/MYU and miR-184/3' UTR of c-Myc (Fig. 7C and D). We constructed luciferase reporters containing full-length MYU or mutated miR-184 binding sites or 3' UTR of c-Myc. We found that overexpression of miR-184 mimic (Table IV) reduced luciferase activity of MYU and c-Myc 3'uTR, but not of the empty vector.

Figure 7. MYU upregulates c-Myc by binding to miR-184. (A) The expression of miRNA is significantly downregulated in TCGA PCa tissues. (B) The correlation analysis between MYU and miR-184 in 216 TCGA PCa tissues (r=−0.1966, P<0.0037). (C) Putative MYU base pairing with miR-184 as identified by target prediction algorithms RNAhybrid. (D) Putative c-Myc 3'UTR base pairing with miR-184 as identified by target prediction algorithms. (E) Luciferase activities in Lenti-X™ 293T cells co-transfected with miR-184 and dual luciferase reporter gene containing nothing, MYU or mutant and c-Myc 3'UTR. Data are presented as the relative ratio of the firefly to Renilla luciferase activity. (F) The correlation analysis between MYU and c-Myc expression in 216 TCGA PCa tissues (r=0.3598, P<0.0001). (G) qRT-PCR and western blot analysis of c-Myc expression level in MYU knockdown or overexpressed cells. Western blot analyses confirmed the c-Myc expression levels. (I) CTG assays found that miR-184 mimic overexpression repressed the cell viability in overexpressed MYU PCa cells. Western blot showed that miR-184 overexpression reduced the protein level of c-Myc in MYU-overexpressing cells. The data graphs depict the count number from three independent experiments (means ± SEM; **P<0.05, ***P<0.01, ****P<0.001).
or the mutated reporter vector (Fig. 7E). Next, we explored the effect of MYU on the expression of c-Myc. The expression level of c-Myc was positively correlated with MYU (r=0.3598, P<0.0001) in PCa tissues (Fig. 7F). Furthermore, we detected that MYU knockdown in DU145 cells decreased the mRNA and protein level of c-Myc. Inversely, MYU overexpression in PC3 cells increased c-Myc expression (Fig. 7G). In addition, c-Myc knockdown suppressed the proliferation of PC3 cells and inhibited the effect of MYU overexpression on promoting cell proliferation. Additionally, the protein level of c-Myc was consistent with the cell proliferation (Fig. 7H), indicating that c-Myc can partly influence MYU. To further clarify the relationship of MYU, miR-184 and c-Myc, we transfected miR-184 mimics into MYU-overexpressing PC3 cells. We found that overexpression of miR-184 significantly abrogated the effect of MYU overexpression on promoting cell proliferation and suppressed the protein level of c-Myc (Fig. 7I). On the base of the above findings, MYU likely regulates c-Myc by functioning as ceRNA to sponge miR-184.

**Figure 8.** Exosome-contained MYU functions in PCa cells. (A) NanoSight particle analysis showing the size and number of exosomes. (B) Western blot analysis confirmed exosomal purity by detecting TSG-101, CD9, and β-actin. (C) qRT-PCR analysis of MYU from MYU-overexpressing or control PC3 cells and exosomes. (D) qRT-PCR analysis of MYU from exosomes treated with RNase A (50 µg/ml) alone or combined with Triton X-100 (0.1%) (P<0.0001) for 40 min. (E) The relative viability of PC3 cells fed with the exosomes derived from the cells overexpressing MYU or control. (F) The relative migration of PC3 cells that were incubated with exosomes derived from MYU-overexpressing or the control PC3 cells, respectively. Representative graphs are shown. (G) Western blotting demonstrated the c-Myc protein level of PC3 cells fed with the exosomes derived from the cells overexpressing MYU or empty vector. Data represent the mean ± SEM from three independent experiments (*P<0.05; **P<0.01; ***P<0.001). NS, not significant.

**Figure 9.** A schematic model of lncRNA MYU functions in PCa cells. lncRNA MYU, which is upregulated in PCa tissues, promotes PCa cell proliferation and migration. Furthermore, MYU can be packaged into exosomes and function in recipient cells. Mechanistically, MYU upregulates c-Myc expression by competitively binding miR-184.
proteins, mRNAs, miRNAs and lncRNAs, may participate in the biological effects in cancer cells (35,36). To examine whether MYU is present in exosomes, we isolated exosomes from the culture medium of MYU-overexpressing or control PC3 cells. Nanosight particle tracking analysis demonstrated the size and number of exosomes (Fig. 8A). Western blot analysis further confirmed their identity by the exosomal markers TSG-101 and CD9 (Fig. 8B). We detected the expression level of MYU by qRT-PCR in the exosomes of both PC3 cell lines. There was a significant upregulation of MYU in the exosomes isolated from the MYU-overexpressing cells, which was consistent with the cellular expression (Fig. 8C). We next investigated the existing pattern of MYU from exosomes. The levels of MYU were unchanged upon RNase A treatment but significantly decreased after being treated with RNase A and Triton X-100 (Fig. 8D), indicating that MYU was mainly wrapped by the membrane of exosomes. These findings suggest that MYU can be delivered into the extracellular milieu by exosomes. In order to explore whether exosome-contained MYU can function in neighboring cells, we purified exosomes and then fed PC3 cells. The CTG (Fig. 8E) and Transwell chamber assays (Fig. 8F) demonstrated that exosomes from the MYU-overexpressing PC3 cells significantly increased proliferation and migration ability of recipient cells, compared to those from control cells. Correspondingly, the c-Myc protein level was significantly increased in the recipient PC3 cells fed with exosomes from the MYU-overexpressing cells (Fig. 8G). These findings suggest that MYU can be delivered into the extracellular milieu by exosomes, and then function in other PCa cells.

Discussion

In the present study, we found that MYU promotes PCa cell proliferation, migration and the exosome is the carrier for extracellular MYU. Mechanistically, MYU likely promotes proliferation of PCa cells by competitively binding miR-184, increasing the expression of c-Myc (Fig. 9).

MYU is expressed in various tumors with a broad spectrum. MYU has been reported to regulate CRC based on its annotated sequence (14,15). However, its future application may be limited due to the lack of an accurate transcript. Generally, lncRNAs play oncogenic or suppressive roles in the biological processes of cancer through various mechanisms (37,38). A recent study indicates that the expression of MYU in CRC is higher than that noted in normal tissues and shortens overall survival time (15). However, Chen et al. found that the deregulation of MYU can be used as an indicator for predicting poor overall and disease-free survival of GC patients (16). These results showed that MYU plays different roles in CRC and GC. In this study, we found that MYU likely promotes PCa cell proliferation and migration. Therefore, MYU may function as an oncogene in PCa.

The exosome is a discoid vesicle that is 40-150 nm in diameter and is released into the extracellular milieu upon fusion with the cellular membrane (39). Exosomes participate in intercellular communication by transmitting intracellular cargoes, such as proteins and nucleic acids (40). A recent study reported that lncRNAs are present in exosomes and account for 20.19% of exosomal RNA extracted from the plasma of castration-resistant PCa patients (41). In this study, we detected that lncRNA MYU exists in the extracellular milieu of PC3 cells, which can be wrapped by exosomes, and promotes recipient cell proliferation and migration. Overall, MYU functions in the extracellular milieu of PCa cells by exosome transportation.

LncRNAs act as ceRNAs to sponge miRNAs leading to release of downstream target genes, which was a canonical model, to study the molecular mechanism of lncRNAs (12,13). In this study, we found that MYU likely upregulates c-Myc expression by sponging miR-184 (Fig. 9). A recent report demonstrated that MYU is a direct target lncRNA of the Wnt/c-Myc pathway and participates in the tumorigenicity of colon cancer cells (14). These results indicate that MYU and c-Myc may form a feedback loop to regulate each other. In conclusion, we demonstrated that MYU displays oncogenic activity by regulating c-Myc expression in PCa, suggesting that MYU maybe as a potential diagnostic predictor and therapeutic target for PCa.

Acknowledgements

Not applicable.

Funding

This work was supported by grants from the National Natural Science Foundation of China (81773023 and 81472827), the National Key R&D Program of China (2016YFC1302100), Hundred-Talent Program (YS21031102) and Frontier Research Program (QYZDB-SSW-SMC038) of the Chinese Academy of Sciences to SG.

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors’ contributions

SG and JW conceived and designed the study. JW performed the experiments. JW and SG wrote the paper. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.